Azilsartan: Difference between revisions
(Created page with "__NOTOC__ {{Azilsartan kamedoxomil}} {{CMG}}; {{AE}} {{SS}} '''''For patient information about Azilsartan kamedoxomil, click Azilsartan kamedoxomil (patient information)|he...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Azilsartan | {{Azilsartan}} | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
'''''For patient information about Azilsartan | '''''For patient information about Azilsartan, click [[Azilsartan (patient information)|here]].''''' | ||
{{SB}} EDARBI<sup>®</sup> | {{SB}} EDARBI<sup>®</sup> | ||
| Line 9: | Line 9: | ||
==Overview== | ==Overview== | ||
'''Azilsartan''' ([[International Nonproprietary Name|INN]], codenamed TAK-536) is an [[angiotensin II receptor antagonist]] used in the treatment of hypertension that was developed by [[Takeda Pharmaceutical Company|Takeda]]. | '''Azilsartan''' ([[International Nonproprietary Name|INN]], codenamed TAK-536) is an [[angiotensin II receptor antagonist]] used in the treatment of hypertension that was developed by [[Takeda Pharmaceutical Company|Takeda]]. | ||
It is marketed in tablet form under the trade name '''Edarbi''' as the [[prodrug]] '''azilsartan medoxomil''' (INN, codenamed TAK-491). On 25 February 2011, the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults.<ref>{{cite press release |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244722.htm |title=FDA approves Edarbi to treat high blood pressure | publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) | date = February 25, 2011 |accessdate=2011-03-01}}</ref> On March 8, 2012, [[Health Canada]] approved the drug for mild to moderate essential hypertension. <ref>[http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/nd_ad_2012_edarbi_145305-eng.php Notice of Decision for EDARBI]</ref> | It is marketed in tablet form under the trade name '''Edarbi''' as the [[prodrug]] '''azilsartan medoxomil''' (INN, codenamed TAK-491). On 25 February 2011, the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults.<ref>{{cite press release |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244722.htm |title=FDA approves Edarbi to treat high blood pressure | publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) | date = February 25, 2011 |accessdate=2011-03-01}}</ref> On March 8, 2012, [[Health Canada]] approved the drug for mild to moderate essential hypertension. <ref>[http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/nd_ad_2012_edarbi_145305-eng.php Notice of Decision for EDARBI]</ref> | ||
| Line 18: | Line 18: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[Azilsartan | ''' [[Azilsartan indications and usage|Indications and Usage]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan dosage and administration|Dosage and Administration]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan contraindications|Contraindications]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan adverse reactions|Adverse Reactions]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan drug interactions|Drug Interactions]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan use in specific populations|Use in Specific Populations]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan overdosage|Overdosage]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan description|Description]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan clinical studies|Clinical Studies]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan patient counseling information|Patient Counseling Information]]''' | ||
'''| [[Azilsartan | '''| [[Azilsartan labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 21:53, 19 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Azilsartan, click here.
Synonyms / Brand Names: EDARBI®
Overview
Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension that was developed by Takeda.
It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults.[1] On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. [2]
Category
Category:Angiotensin II receptor antagonists;Benzimidazoles;Carbamates;Ethers;Cardiovascular Drugs
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.
An AT2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the AT1 receptor than for the AT2 receptor.
Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation.
Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure.
References
- ↑ "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration (FDA). February 25, 2011. Retrieved 2011-03-01.
- ↑ Notice of Decision for EDARBI